Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/ Refractory T-cell Malignancies”

1,694 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,694 results

Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Testing effectiveness (Phase 2)UnknownNCT04296786
What this trial is testing

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Who this might be right for
Cutaneous T-cell Lymphoma
Peking Union Medical College Hospital 52
Early research (Phase 1)Looking for participantsNCT07007117
What this trial is testing

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

Who this might be right for
Refractory NeuroblastomaRelapsed NeuroblastomaHigh-Risk Neuroblastoma
Stephan Grupp MD PhD 38
Very early researchLooking for participantsNCT06092047
What this trial is testing

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

Who this might be right for
CD19-positive Relapsed or Refractory B-cell Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)Looking for participantsNCT07341191
What this trial is testing

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Who this might be right for
Mantle Cell Lymphoma
Canadian Cancer Trials Group 40
Early research (Phase 1)UnknownNCT04861480
What this trial is testing

Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Chongqing Precision Biotech Co., Ltd 18
Very early researchLooking for participantsNCT07144020
What this trial is testing

Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Zhejiang University 50
Testing effectiveness (Phase 2)Looking for participantsNCT05996185
What this trial is testing

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Who this might be right for
T Cell LymphomaT-cell Lymphoma
Yale University 22
Not applicableUnknownNCT00295997
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersKidney CancerLeukemia+4 more
University of California, San Francisco 35
Testing effectiveness (Phase 2)Looking for participantsNCT06378190
What this trial is testing

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

Who this might be right for
Refractory B-Cell LymphomaB-cell Lymphoma Recurrent
Instituto de Investigación Biomédica de Salamanca 27
Early research (Phase 1)UnknownNCT05457010
What this trial is testing

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Arcellx, Inc. 24
Testing effectiveness (Phase 2)Looking for participantsNCT05594797
What this trial is testing

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Who this might be right for
Multiple Myeloma
Hrain Biotechnology Co., Ltd. 100
Early research (Phase 1)Looking for participantsNCT06934382
What this trial is testing

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Who this might be right for
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Stephan Grupp MD PhD 33
Early research (Phase 1)WithdrawnNCT03904069
What this trial is testing

Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia
Amgen
Testing effectiveness (Phase 2)UnknownNCT04052659
What this trial is testing

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Who this might be right for
Peripheral T-cell Lymphoma
Peking University 30
Testing effectiveness (Phase 2)UnknownNCT04470141
What this trial is testing

SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma

Who this might be right for
Peripheral T Cell Lymphoma
Nanjing Sanhome Pharmaceutical, Co., Ltd. 130
Testing effectiveness (Phase 2)Study completedNCT04601831
What this trial is testing

'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL

Who this might be right for
Non-Hodgkin Lymphoma
University of Texas Southwestern Medical Center 14
Early research (Phase 1)WithdrawnNCT04094766
What this trial is testing

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Who this might be right for
Refractory B Acute Lymphoblastic LeukemiaRelapse B Acute Lymphoblastic Leukemia
Second Affiliated Hospital of Xi'an Jiaotong University
Very early researchUnknownNCT04156269
What this trial is testing

BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
iCell Gene Therapeutics 12
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Load More Results